HRMY Harmony Biosciences Holdings Inc.

26.16
-0.06  -0%
Previous Close 26.22
Open 26.14
52 Week Low 25.46
52 Week High 52.74
Market Cap $1,488,529,925
Shares 56,900,991
Float 17,895,401
Enterprise Value $1,545,687,984
Volume 134,165
Av. Daily Volume 295,914
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
WAKIX (pitolisant)
Excessive daytime sleepiness associated with Prader-Willi Syndrome
Phase 2
Phase 2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
WAKIX (pitolisant)
Myotonic dystrophy
Phase 2
Phase 2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
WAKIX (pitolisant)
Adult cataplexy
Approved
Approved
FDA approval announced October 14, 2020.

Latest News

  1. PLYMOUTH MEEETING, Pa., July 29, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced that John C. Jacobs, President and CEO, has been named an EY Entrepreneur Of The Year® 2021 Greater Philadelphia Award Winner.

    Jacobs was selected by a panel of independent judges for his work leading Harmony and joins an esteemed multi-industry community of other entrepreneurs who have driven their companies' success, transformed their industries, and made a positive impact on their employees and communities.

    "I am extremely honored to be selected for this prestigious award and accept it on behalf of the entire Harmony team, who demonstrate their commitment and passion every day through their support of the rare disease community," said John C. Jacobs, President and CEO. "I'm also inspired by the opportunity we have as a company to help patients in need who are living with rare neurological disorders. As Harmony continues to grow and evolve into a leading rare disease company, it is our vision of being able to help an even broader population of patients that drives us forward."

    For 35 years, the EY Entrepreneur Of The Year Award® program has been one of the preeminent competitive awards for entrepreneurs and leaders of high-growth companies. The award recognizes entrepreneurial leaders who are excelling in overcoming adversity, driving financial performance, and committed to building innovative and values-based companies with wider social impact.

    As a Greater Philadelphia award winner, Jacobs is now eligible for consideration for the Entrepreneur Of The Year® 2021 National Awards.

    About Harmony Biosciences 

    Harmony Biosciences is a pharmaceutical company headquartered in Plymouth Meeting, PA. The Company was established by Paragon Biosciences, LLC, with a vision to provide novel treatment options for people living with rare neurological disorders who have unmet medical needs. For more information on Harmony, please visit the company's website: www.harmonybiosciences.com.

    About Entrepreneur Of The Year®

    Entrepreneur Of The Year® is the world's most prestigious business awards program for unstoppable entrepreneurs. These visionary leaders deliver innovation, growth and prosperity that transform our world. The program engages entrepreneurs with insights and experiences that foster growth. It connects them with their peers to strengthen entrepreneurship around the world. Entrepreneur Of The Year is the first and only truly global awards program of its kind. It celebrates entrepreneurs through regional and national awards programs in more than 145 cities in over 60 countries. National Overall winners go on to compete for the EY World Entrepreneur Of The Year™.

    Harmony Biosciences Media Contact:

    Nancy Leone

    215-891-6046

    Harmony Biosciences Investor Contact: 

    Lisa Caperelli 

    484-539-9736 

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/john-c-jacobs-president-and-ceo-of-harmony-biosciences-named-an-ernst--young-ey-entrepreneur-of-the-year-2021-greater-philadelphia-award-winner-301343799.html

    SOURCE Harmony Biosciences

    View Full Article Hide Full Article
  2. PLYMOUTH MEETING, Pa., July 27, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced that it will issue a press release on the Company's second quarter 2021 financial results on Tuesday, August 10, 2021 at 8:00 a.m. ET. Following the release, Harmony will conduct a conference call and live webcast on the same day, at 8:30 a.m. ET.

    To participate in the call, please dial (833) 614-1471 (domestic) or +1 (914) 987-7209 (international), and reference passcode 2955734. It is recommended that you dial in at least 10 minutes prior to the call.

    The live and replayed webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/.

    A replay of the call will be available within 24 hours by dialing (855) 859-2056 (domestic) or +1 (404) 537-3406 (international) and entering conference ID: 2955734. The replay will be available until August 17, 2021.

    About Harmony Biosciences

    Harmony Biosciences is a pharmaceutical company headquartered in Plymouth Meeting, PA. The Company was established by Paragon Biosciences, LLC, with a vision to provide novel treatment options for people living with rare neurological disorders who have unmet medical needs. For more information on Harmony, please visit the company's website: www.harmonybiosciences.com.

    Harmony Biosciences Investor Contact:

    Lisa Caperelli

    610-608-0215

    Harmony Biosciences Media Contact:

    Nancy Leone

    215-891-6046

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/harmony-biosciences-announces-date-of-second-quarter-2021-financial-results-301341458.html

    SOURCE Harmony Biosciences

    View Full Article Hide Full Article
  3. PLYMOUTH MEETING, Pa., June 29, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced initiation of a Phase 2 clinical trial to evaluate the safety and efficacy of pitolisant for excessive daytime sleepiness (EDS) and other non-muscular symptoms in adult patients with type 1 myotonic dystrophy (DM1).

    "In addition to the primary symptoms of myotonia and muscle weakness in patients with type 1 myotonic dystrophy, the non-muscular symptoms of excessive daytime sleepiness, fatigue, and cognitive dysfunction are very common in these patients and have a negative impact on daily functioning as much as, or more so, than the primary muscle symptoms of the disease," said Harmony's Chief Medical Officer, Jeffrey Dayno, M.D. "Pitolisant's novel mechanism of action increases histamine transmission in the brain which provides the scientific rationale for its potential clinical utility for the common non-muscular symptoms in patients with DM1. We listened to the needs of patients and caregivers in the myotonic dystrophy patient community and are pleased to have initiated this Phase 2 clinical trial to assess the potential clinical benefit of pitolisant in patients with this rare neurological disease, for which there are currently no approved treatment options."

    Myotonic dystrophy is the most common form of adult-onset muscular dystrophy. It is a genetic disorder inherited in an autosomal-dominant pattern. Latest estimates suggest a prevalence of about one per 2,100 people with the genetic defect for DM1, which is the most common form of this disorder. This equates to about 160,000 people in the U.S. with the genetic defect for DM1. Estimates suggest there are 40,000 people currently diagnosed with DM1 in the U.S., with up to 90% of them reporting EDS and fatigue and over 60% of them experiencing cognitive dysfunction.

    The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of pitolisant in patients with DM1 ages 18 – 65 years. Approximately 135 patients will be randomized at baseline to low-dose pitolisant, high-dose pitolisant, or placebo in a 1:1:1 treatment ratio titrated over three weeks, followed by eight weeks of stable dosing. Patients who complete the randomized, controlled phase of the trial will be eligible to participate in an open-label extension phase to assess the long-term safety and effectiveness of pitolisant in patients with DM1.

    The primary objective of the trial is to evaluate the effect of pitolisant compared with placebo on EDS. Secondary objectives include assessments of fatigue, specific measures of cognitive function using validated computer-based assessments, and overall disease burden utilizing a disease-specific, patient-reported outcomes instrument for DM1. Topline results are anticipated from the Phase 2 trial in the second half of 2022.

    Pitolisant is marketed as WAKIX® in the U.S. for the treatment of EDS or cataplexy in adult patients with narcolepsy.

    About WAKIX® (pitolisant) Tablets

    WAKIX, a first-in-class medication, is approved by the U.S. Food and Drug Administration for the treatment of excessive daytime sleepiness or cataplexy in adult patients with narcolepsy. WAKIX has been commercially available in the U.S. since Q4 2019. It was granted orphan drug designation for the treatment of narcolepsy in 2010, and breakthrough therapy designation for the treatment of cataplexy in 2018. WAKIX is a selective histamine 3 (H3) receptor antagonist/inverse agonist. The mechanism of action of WAKIX is unclear; however, its efficacy could be mediated through its activity at H3 receptors, thereby increasing the synthesis and release of histamine, a wake promoting neurotransmitter. WAKIX was designed and developed by Bioprojet (France). Harmony has an exclusive license from Bioprojet to develop, manufacture and commercialize pitolisant in the United States. 

    Important Safety Information

    WAKIX is contraindicated in patients with known hypersensitivity to pitolisant or any component of the formulation and in patients with severe hepatic impairment. WAKIX is extensively metabolized by the liver and there is a significant increase in WAKIX exposure in patients with moderate impairment.

    WAKIX prolongs the QT interval. Avoid use of WAKIX in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval. Avoid use of WAKIX in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and the presence of congenital prolongation of the QT interval.

    The risk of QT prolongation may be greater in patients with hepatic or renal impairment due to higher concentrations of pitolisant; monitor these patients for increased QTc. Dosage modification is recommended in patients with moderate hepatic impairment and moderate or severe renal impairment. WAKIX is not recommended in patients with end-stage renal disease (ESRD).

    In the placebo-controlled clinical trials conducted in patients with narcolepsy with or without cataplexy, the most common adverse reactions (≥5% and twice placebo) for WAKIX were insomnia (6%), nausea (6%), and anxiety (5%). Other adverse reactions that occurred at ≥2% and more frequently than in patients treated with placebo included headache, upper respiratory infection, musculoskeletal pain, heart rate increased, hallucinations, irritability, abdominal pain, sleep disturbance, decreased appetite, cataplexy, dry mouth, and rash.

    Please see the Full Prescribing Information for WAKIX for more information.

    About Harmony Biosciences 

    Harmony Biosciences is a pharmaceutical company headquartered in Plymouth Meeting, PA. The Company was established by Paragon Biosciences, LLC, with a vision to provide novel treatment options for people living with rare neurological disorders who have unmet medical needs. For more information on Harmony, please visit the company's website: www.harmonybiosciences.com.

    Forward Looking Statement

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding our product WAKIX. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our commercialization efforts and strategy for WAKIX; the rate and degree of market acceptance and clinical utility of WAKIX, pitolisant in additional indications, if approved, and any other product candidates we may develop or acquire, if approved; our research and development plans, including our plans to explore the therapeutic potential of pitolisant in additional indications; our ongoing and planned clinical trials; our ability to expand the scope of our license agreement with Bioprojet; the availability of favorable insurance coverage and reimbursement for WAKIX; the impact of the COVID-19 pandemic; the timing of and our ability to obtain regulatory approvals for pitolisant for other indications as well as any other product candidates; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; our ability to identify additional products or product candidates with significant commercial potential that are consistent with our commercial objectives; our commercialization, marketing and manufacturing capabilities and strategy; significant competition in our industry; our intellectual property position; loss or retirement of key members of management; failure to successfully execute our growth strategy, including any delays in our planned future growth; our failure to maintain effective internal controls; the impact of government laws and regulations; volatility and fluctuations in the price of our common stock; and the significant costs and required management time as a result of operating as a public company; the fact that the price of Harmony's common stock may be volatile and fluctuate substantially; significant costs and required management time as a result of operating as a public company. These and other important factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 25, 2021, and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

    Harmony Biosciences Media Contact: 

    Nancy Leone 

    215-891-6046 

     

    Harmony Biosciences Investor Contact: 

    Lisa Caperelli 

    484-539-9736 

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/harmony-biosciences-initiates-a-phase-2-clinical-trial-in-myotonic-dystrophy-301321420.html

    SOURCE Harmony Biosciences

    View Full Article Hide Full Article
  4. PLYMOUTH MEETING, Pa., June 10, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced results of a new analysis evaluating number needed to treat (NNT) and effect sizes for treatment with WAKIX® (pitolisant) that demonstrates the magnitude of its clinical effectiveness for excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy. The poster was presented at the 35th Annual Meeting of the Associated Professional Sleep Societies (APSS), known as "SLEEP 2021," held virtually June 10-13.

    PLYMOUTH MEETING, Pa., June 10, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced results of a new analysis evaluating number needed to treat (NNT) and effect sizes for treatment with WAKIX® (pitolisant) that demonstrates the magnitude of its clinical effectiveness for excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy. The poster was presented at the 35th Annual Meeting of the Associated Professional Sleep Societies (APSS), known as "SLEEP 2021," held virtually June 10-13.

    "Excessive daytime sleepiness or impaired wakefulness can often result in brain fog, fatigue, changes in mood and other symptoms that have a large physical, emotional and psychological impact on a patient's life," said Harmony's Chief Medical Officer, Jeffrey Dayno, M.D. "We're encouraged to see our data supporting the clinical utility of WAKIX and its value as an effective and safe treatment option to help this patient population." 

    Assessment of the Clinical Benefits of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy

    This poster presents results from a new analysis that evaluated the clinical impact of pitolisant in adults with narcolepsy using NNT and effect sizes as response to treatment metrics based on data from the HARMONY 1 and HARMONY CTP randomized, controlled clinical trials. NNT and effect size are important metrics as they measure the number of patients that need to be treated to achieve a specific outcome for one person and the magnitude of drug–placebo difference on outcome measures, respectively.

    At week 8 in the HARMONY 1 trial (pitolisant, n=31; placebo, n=30), pitolisant had a NNT of 5 with 67.7% of patients treated with pitolisant achieving treatment response for EDS compared to placebo (43.3%) and effect size was 0.61 based on change in Epworth Sleepiness Scale scores compared to baseline.

    At week 7 in the HARMONY CTP trial (pitolisant, n=54, placebo, n=51), pitolisant had a NNT of 3 with 68.6% and 66.7% of patients treated with pitolisant achieving treatment response for EDS and for cataplexy respectively compared to placebo (34% and 25.5%). Effect size was 0.86 based on changes in the Epworth Sleepiness Scale score and weekly rate of cataplexy compared to baseline.

    About WAKIX® (pitolisant) Tablets

    WAKIX, a first-in-class medication, is approved by the U.S. Food and Drug Administration for the treatment of excessive daytime sleepiness or cataplexy in adult patients with narcolepsy. WAKIX has been commercially available in the U.S. since Q4 2019. It was granted orphan drug designation for the treatment of narcolepsy in 2010, and breakthrough therapy designation for the treatment of cataplexy in 2018. WAKIX is a selective histamine 3 (H3) receptor antagonist/inverse agonist. The mechanism of action of WAKIX is unclear; however, its efficacy could be mediated through its activity at H3 receptors, thereby increasing the synthesis and release of histamine, a wake promoting neurotransmitter. WAKIX was designed and developed by Bioprojet (France). Harmony has an exclusive license from Bioprojet to develop, manufacture and commercialize pitolisant in the United States. 

    Important Safety Information

    WAKIX is contraindicated in patients with known hypersensitivity to pitolisant or any component of the formulation and in patients with severe hepatic impairment. WAKIX is extensively metabolized by the liver and there is a significant increase in WAKIX exposure in patients with moderate impairment.

    WAKIX prolongs the QT interval. Avoid use of WAKIX in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval. Avoid use of WAKIX in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and the presence of congenital prolongation of the QT interval.

    The risk of QT prolongation may be greater in patients with hepatic or renal impairment due to higher concentrations of pitolisant; monitor these patients for increased QTc. Dosage modification is recommended in patients with moderate hepatic impairment and moderate or severe renal impairment. WAKIX is not recommended in patients with end-stage renal disease (ESRD).

    In the placebo-controlled clinical trials conducted in patients with narcolepsy with or without cataplexy, the most common adverse reactions (≥5% and twice placebo) for WAKIX were insomnia (6%), nausea (6%), and anxiety (5%). Other adverse reactions that occurred at ≥2% and more frequently than in patients treated with placebo included headache, upper respiratory infection, musculoskeletal pain, heart rate increased, hallucinations, irritability, abdominal pain, sleep disturbance, decreased appetite, cataplexy, dry mouth, and rash.

    Please see the Full Prescribing Information for WAKIX for more information.

    About Narcolepsy  

    Narcolepsy is a rare, chronic, debilitating neurological disorder of sleep-wake state instability that impacts approximately 165,000 Americans and is primarily characterized by excessive daytime sleepiness (EDS) and cataplexy – its two cardinal symptoms – along with other manifestations of REM sleep dysregulation, which intrude into wakefulness. EDS is the inability to stay awake and alert during the day and is the symptom that is present in all people living with narcolepsy. In most patients, narcolepsy is caused by the loss of hypocretin, a neuropeptide in the brain that supports sleep-wake state stability. This disorder affects men and women equally, with typical symptom onset in adolescence or young adulthood; however, it can take up to a decade to be properly diagnosed. 

    About Harmony Biosciences 

    Harmony Biosciences is a pharmaceutical company headquartered in Plymouth Meeting, PA. The Company was established by Paragon Biosciences, LLC, with a vision to provide novel treatment options for people living with rare neurological disorders who have unmet medical needs. For more information on Harmony, please visit the company's website: www.harmonybiosciences.com.

    Forward Looking Statement

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding our product WAKIX. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our commercialization efforts and strategy for WAKIX; the rate and degree of market acceptance and clinical utility of WAKIX, pitolisant in additional indications, if approved, and any other product candidates we may develop or acquire, if approved; our research and development plans, including our plans to explore the therapeutic potential of pitolisant in additional indications; our ongoing and planned clinical trials; our ability to expand the scope of our license agreement with Bioprojet; the availability of favorable insurance coverage and reimbursement for WAKIX; the impact of the COVID-19 pandemic; the timing of and our ability to obtain regulatory approvals for pitolisant for other indications as well as any other product candidates; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; our ability to identify additional products or product candidates with significant commercial potential that are consistent with our commercial objectives; our commercialization, marketing and manufacturing capabilities and strategy; significant competition in our industry; our intellectual property position; loss or retirement of key members of management; failure to successfully execute our growth strategy, including any delays in our planned future growth; our failure to maintain effective internal controls; the impact of government laws and regulations; volatility and fluctuations in the price of our common stock; and the significant costs and required management time as a result of operating as a public company; the fact that the price of Harmony's common stock may be volatile and fluctuate substantially; significant costs and required management time as a result of operating as a public company. These and other important factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 25, 2021, and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

    Harmony Biosciences Media Contact: 

    Nancy Leone 

    215-891-6046 

     

    Harmony Biosciences Investor Contact: 

    Lisa Caperelli 

    484-539-9736 

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/harmony-biosciences-presents-new-analysis-of-clinical-impact-for-wakix-pitolisant-at-the-sleep-2021-annual-meeting-301309651.html

    SOURCE Harmony Biosciences

    View Full Article Hide Full Article
  5. PLYMOUTH MEETING, Pa., June 9, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced applications for its Patients at the Heart Grant Program open Wednesday, June 9, 2021 for patient-centric organizations working to support and address the challenges of people living with sleep disorders and rare diseases who experience excessive daytime sleepiness (EDS).

    The Patients at the Heart Grant, a competitive grant opportunity, was developed to underscore Harmony's ongoing commitment to support the comprehensive needs of people affected by sleep disorders. Since its launch in 2019, awards have funded innovative patient-centric programs, with the most recent grants specifically awarded to programs created to support and address the unique challenges of people living with narcolepsy during the COVID-19 pandemic.

    "Our goal is to improve the lives of people living with sleep disorders and their families, and through these innovative programs, we have the opportunity to partner with and make a positive difference for these patient communities," said Cate McCanless, Harmony's Senior Vice President, Corporate Affairs and Public Policy.

    This year's charitable grant applications should focus on one or more of the following categories:

    • Programs that support persons with sleep disorders or rare diseases who experience EDS to live a fuller, more engaged life.
    • Programs that address the psycho-social challenges faced by persons or caregivers of persons with sleep disorders or rare diseases who experience EDS.
    • Programs that improve the overall support of family members of persons living with sleep disorders or rare diseases who experience EDS.
    • Creation of educational materials to increase awareness and reduce time to diagnosis of persons with sleep disorders or rare diseases who experience EDS.

    Applications from eligible organizations are being accepted beginning Wednesday, June 9, 2021 through Friday, August 20, 2021. Announcement of grant recipients will take place in September 2021. For more information, please visit https://www.harmonybiosciences.com/grant-programs/patients-at-the-heart/ for a program overview document and application. Grants can be submitted to .

    About Harmony Biosciences 

    Harmony Biosciences is a pharmaceutical company headquartered in Plymouth Meeting, PA. The Company was established by Paragon Biosciences, LLC, with a vision to provide novel treatment options for people living with rare neurological disorders who have unmet medical needs. For more information on Harmony, please visit the company's website: www.harmonybiosciences.com.

    Harmony Biosciences Media Contact: 

    Nancy Leone 

    215-891-6046 

     

    Harmony Biosciences Investor Contact: 

    Lisa Caperelli 

    484-539-9736 

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/harmony-biosciences-announces-applications-for-2021-patients-at-the-heart-grant-program-open-june-9-301308371.html

    SOURCE Harmony Biosciences

    View Full Article Hide Full Article
View All Harmony Biosciences Holdings Inc. News